Introduction
============

Posterior reversible encephalopathy syndrome (PRES) is a clinico-radiological syndrome defined in 1996. Clinically, it is characterized by headache, changes in mental status, seizures, and visual disturbances ([@B1]). In many cases, severe headache is associated with a sudden rise in blood pressure ([@B2]). Except for hypertensive encephalopathy, etiology of PRES includes preeclampsia ([@B3],[@B4]), sepsis ([@B4]), acute glomerulonephritis ([@B5],[@B6]), lupus nephritis ([@B7]), organ transplantation ([@B8]), peritoneal dialysis ([@B9]), usage of cyclosporine A ([@B1]), tacrolimus ([@B10],[@B11]), intrathecal methotrexate, cytarabine, daunorubicin, vincristine, and L-asparaginase ([@B12]). Although hypertension is frequent, 20%-30% are normotensive ([@B10], [@B13]).

Pathogenesis is based on transient changes in the posterior circulation of the brain. Neuro-imaging is important for diagnosis. Computed tomography (CT) or magnetic resonance imaging (MRI) reveal diffuse edema more prominent in the parietal and occipital lobes bilaterally ([@B4],[@B14]). Elimination of the underlying etiology and regulation of blood pressure are the first measures in PRES ([@B8],[@B13]).

Patients diagnosed and treated rapidly may recover completely within a few weeks. Due to the lack of specific clinical symptoms of the syndrome, it can be confused with other clinical diagnoses which may lead to unnecessary or inappropriate treatments ([@B4],[@B14]).

In this study, clinical and radiological findings of children diagnosed with PRES in our clinics were reviewed.

Materials and Methods
=====================

We retrospectively analyzed the data of 23 pediatric patients who received the diagnosis of PRES from Mar 2010-Apr 2015 in various units of Inonu University Turgut Ozal Medical Center in Turkey: organ and bone marrow transplantation unit, Pediatric Intensive Care, Pediatric subspecialty departments of Gastroenterology, Oncology, Nephrology, or Rheumatology. Criteria for inclusion were 1) symptoms and signs compatible with PRES such as seizures, headache, visual disturbances, and altered mental function on a background of underlying primary disease, and 2) supportive imaging findings. Demographic data, clinical findings, neurological signs, length of hospital stay, concurrent medical illnesses, recently used drugs, blood pressure values during the symptoms, and cranial MRI findings were recorded. Hypertension was defined as systolic and/or diastolic blood pressure values higher than the 95% percentile for age ([@B15]).

MRI studies were performed on 1.5 Tesla MRI devices (Magnetom; Siemens, Germany). T2-weighted axial and sagittal, fluid-attenuated inversion recovery (FLAIR) axial, T1-weighted axial contrast-enhanced and unenhanced images were taken. Diffusion-weighted images and values were used and ADC maps were obtained. Cranial MRI was performed on all patients within the first three days after the onset of neurological symptoms. At least one more brain MRI was made during the follow-up. Two neuroradiologists interpreted all images. Typical MRI findings were defined as hyperintensity in subcortical white matter on T2A and FLAIR images and increase in ADC values in the posterior parietal, occipital, and temporal areas. Atypical MRI findings were defined as frontal lobe, brain stem, and cerebellar involvements, cytotoxic edema, hemorrhage, and contrast enhancement.

This study was performed with approval from the Institutional Review Board of Inonu University Research Council.

Results
=======

There were 23 children aged 1-16 (mean 7.8) yr, 13 boys, and 10 girls. Demographic and clinical data are summarized in [Table 1](#T1){ref-type="table"}. Among underlying primary diseases, malignancies (7/23), liver transplantation (7/23), and chronic renal diseases (3/23 chronic renal failure, 1/23 membranoproliferative glomerulonephritis, 1/23 lupus nephritis, 1/23 nephrotic syndrome), were most common ([Table 1](#T1){ref-type="table"}). Hypertension was the triggering factor in 78.2% of the cases, followed by immunosuppressive and antineoplastic agents (55.5%), liver transplantation (22.2%), and peritoneal dialysis (16.6%). Clinical signs suggesting the diagnosis of PRES: lethargy, confusion, coma, and encephalopathy were observed in all cases. Other clinical signs were seizures (95.6%), headache (60.8%), and visual impairment (21.7%). Seizure types were generalized (67.6%), partial (24.6%) or secondary generalized (7.8%).

Cranial imaging and EEG findings, clinical course, and antiepileptic drugs are summarized in [Table 2](#T2){ref-type="table"}. Cranial CT was performed in 16 patients: of these, four (25%) showed hypodense areas in posterior brain regions and hemispheres. Cranial MRI was performed at diagnosis in all, and on follow-up in 17 patients. Initial MRIs of all patients showed bilateral symmetric hyperintense lesions in occipital subcortical white matter on T2-weighted and FLAIR sequences, and hypointense lesions and vasogenic edema on T1-weighted images ([Figures 1](#F1){ref-type="fig"},[2](#F2){ref-type="fig"}). In addition, frontal (13/23), parietal (12/23) and temporal (7/23) lobe involvements followed by cerebellum (6/23), basal ganglia (5/23), corpus callosum (7/23), brainstem (2/23), insular cortex (1/23), and thalamus (3/23) were observed. Lesions compatible with cytotoxic edema (11/23), contrast enhancement (1/23), and bleeding (3/23) were associated in certain cases ([Table 2](#T2){ref-type="table"}).

Patients stayed in the pediatric intensive care unit for mean 16.2 (1-120) days. The mean duration of acute encephalopathy was 3.6 (1-10) days. Hypertensive patients were treated with nifedipine, amlodipine, verapamil, captopril, enalapril, furosemide, or losartan. Potential causative drugs such as tacrolimus, cyclosporine, cyclophosphamide, cisplatin, vincristine, L-asparaginase were discontinued. Eighteen patients had a follow-up cranial MRI performed within 2-12 wk (mean 37.6 d) after the first one. Partial resolution of lesions was observed in MRIs performed within the first three weeks, and complete resolution, on those performed at 4 wk or later.

On long-term follow-up, one was lost to follow-up after discharge. Five patients died during the follow-up: the cause of death was neoplasm in three, and chronic liver disease with post-transplant complications in two. No patients died during the PRES episode. Overall, no correlation was detected between underlying disease and clinical or radiological findings.

Discussion
==========

PRES may present with visual symptoms suggestive of posterior cerebral involvement, or with non-specific symptoms such as generalized or focal seizures, headache, nausea, vomiting, and mental changes. On the other hand, radiological findings are diagnostic. Morbidity and mortality in PRES may result from status epilepticus, intracranial hemorrhage or cerebral infarct ([@B11],[@B14],[@B16],[@B17]). The pathophysiology of PRES is explained by two series of events initiated by hypertension: arterial spasm resulting in cytotoxic edema particularly in areas with limited arterial supply, and, more recently and more widely accepted, cerebral hyperperfusion and arterial hydrostatic edema followed by deterioration of cerebral autoregulation. In the 25% cases with normal blood pressure, the scenario is attributed to vasogenic edema due to various causes ([@B8],[@B11],[@B18]-[@B20]). On the other hand, the initiating role of hypertension can also be discussed, as hypertension can be secondary to acute encephalopathy and intracranial pressure. In our study, the predisposing factors were hypertension and antineoplastic or immunosuppressive medications. We had seven post-transplantation cases because our hospital is a transplantation referral center. The use of immunosuppressive agents after transplantation is a risk factor for PRES. It was detected in 4/40 patients with liver transplants ([@B21]). All our patients with organ transplantation had radiological findings other than typical posterior cerebral lesions. The presence of such radiological findings was not predictive of a specific course or outcome.

Our rate of atypical MRI findings, 82.6%, is higher than previously reported: 42.5% of 40 children and 43.8-58% in adult studies ([@B22]-[@B25]). Frontal lobe lesions were predominant. The susceptibility of the anterior cerebral regions to PRES as much as posterior ones may be related to the limitation of the anterior cerebral circulation in children, similar to the vertebro-basilar circulation ([@B26]). Because frontal involvement is frequent in any studies including those of the adult age group, the name of the syndrome as 'posterior' appears misleading. As previously reported, the extent of lesions were not correlated with the type and severity of clinical findings in our cases ([@B4]).

###### 

Demographic Data, Clinical Characteristics, and Management of 23 Cases

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Case   Age/Sex   Underlying Disorder                            Clinical presentation                                                 Precipitating Factors                             Maximal BP\   Antihypertensive agents
                                                                                                                                                                                          (mm/Hg)       
  ------ --------- ---------------------------------------------- --------------------------------------------------------------------- ------------------------------------------------- ------------- ----------------------------------------------
  1      4/M       Acut liver failure, liver transplantation      Mental change, seizures                                               Tacrolimus, liver transplantation                 100/60        \_

  2      9/M       Wilson disease, liver transplantation          Coma                                                                  Cyclosporin,hypertension,\                        145/85        Amlodipine
                                                                                                                                        liver transplantation                                           

  3      16/M      Lymphoblastic lymphoma                         Mental change, seizures, headache                                     Vincristin, L-asparaginase                        110/70        \_

  4      13/M      Chronic renal failure                          Mental change, seizures, headache                                     Hypertension, Peritoneal dialysis                 165/105       Captopril,peritoneal dialysis

  5      7/F       Chronic renal failure                          Mental change, seizures, headache, visual disturbance, papilloedema   Hypertension, Peritoneal dialysis                 150/100       Enalapril,peritoneal dialysis

  6      13/M      Membranoproliferative glomerulonephritis       Mental change, seizures, headache                                     Hypertension                                      185/125       Furosemide, nifedipine\
                                                                                                                                                                                                        hemodialysis

  7      9/F       WilmsTumor                                     Mental change, seizures, headache                                     Vincristine                                       110/65        \_

  8      11/M      Lupus Nephritis                                Mental change, seizures,headache                                      Cyclophosphamide, hypertension                    155/111       Hemodialysis,enalapril, losartan, furosemide

  9      16/F      Chronic liver failure, liver transplantation   Mental change, seizures                                               Tacrolimus,liver transplantation, hypertension    135/95        Amlodipine

  10     10/F      Acute lymphoblastic leukemia                   Mental change, seizures,headache, visual disturbance, papilloedema    Vincristine, L-asparaginase, Hypertension         130/92        Verapamil

  11     9/F       Chronic liver failure                          Mental change, seizures, headache                                     Hypertension                                      140/100       Amlodipine, enalapril, furosemide

  12     5/F       Chronic renal failure                          Mental change, seizures, headache                                     Hypertension, Peritoneal dialysis,                145/100       Enalapril

  13     6/M       Lymphoblastic lymphoma                         Mental change, seizures, headache                                     Hypertension                                      160/121       Amlodipine, enalapril,losartan

  14     9/F       Polyarteritis Nodosa                           Mental change, seizures, headache                                     Hypertension                                      155/106       Verapamil

  15     7/M       Nephrotic Syndrome                             Mental change, seizures, headache                                     Hypertension                                      160/110       Enalapril, losartan

  16     12/F      Wilson disease, liver transplantation          Mental change, seizures, visual disturbance                           Tacrolimus, liver transplantation, hypertension   140/80        Verapamil

  17     8/M       Chronic lymphoblastic leukemia                 Mental change, seizures, visual disturbance,                          Vincristine, L-asparaginase                       140/87        Verapamil

  18     6/M       Acute lymphoblastic leukemia                   Mental change, seizures,visual disturbance,                                                                             130/90        

  19     10/M      Inflamatory bowel disease                      Mental change, seizures ,headache                                     Vincristine, L-asparaginase                       185/110       Ramipril

  20     1/M       Chronic liver failure, liver transplantation                                                                                                                           95/55         Ramipril, losartan

  21     3/F       Acute lymphoblastic leukemia                   Mental change, seizures ,headache                                     Hypertension, total colectomy, tacrolimus         180/100       \_

  22     2/F       Chronic liver failure, liver transplantation   Mental change, seizures                                               Tacrolimus, liver transplantation                 115/65        \_
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Neurologic Investigations and Outcames of 23 Cases

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Case   Brain CT                             Initial MRI findings   Follow up MRI\                             Intensive care\       Recovery\   EEG   Antiepileptic therapy                 Prognosis                  
                                                                     (resolution/ interval)                     Unit staying\         time                                                                               
                                                                                                                time (day)                                                                                               
  ------ ------------------------------------ ---------------------- ------------------------------------------ --------------------- ----------- ----- ------------------------------------- -------------------------- -------------------------
  1      None                                 Prt, Occ               Bg, Frt, cytotoxic edema\                  Subtotal (18 thday)   17          8     None                                  None                       Diplegic cerebral palsy
                                                                     hemorrhage                                                                                                                                          

  2      None                                 Prt, Occ               Frt, Cbl, hemorrhage, Bg, CC\              None                  10          \-    None                                  None                       Exitus
                                                                     Bs, cytotoxicedema                                                                                                                                  

  3      Cerebral atrophy                     Tmp, Occ               Frt, Cbl, CC                               Total (1 month)       2           1     Normal                                Levetiracetam              Exitus

  4      Normal                               Prt, Occ               Frt, cytotoxic edema                       Subtotal (15 thday)   7           3     None                                  Phenytoin                  Recovery

  5      Hypodensities,\                      Prt, Occ               Frt, cytotoxic edema                       None                  7           2     Voltage suppression,\                 Sodyum Valproat            Recovery
         brainedema                                                                                                                                     generalized epileptic abnormalities                              

  6      None                                 Prt, Occ               Frt, Cbl, cytotoxic edema                  Subtotal (20 thday)   10          2     Normal                                None                       Recovery

  7      Normal                               Tmp, Occ               None                                       Total (2 month)       2           2     None                                  None                       Recovery

  8      None                                 Tmp, Occ               None                                       Subtotal (1 month)    3           3     Voltage suppression\                  None                       Recovery
                                                                                                                                                        İsolated sharp waves                                             

  9      Cerebral atrophy                     Prt, Occ               Frt, Cbl, CC                               Total (2 month)       15          10    Normal                                Levetiracetam              Recovery

  10     None                                 Occ                    Cytotoxic edema, Gd+                       Total (3 month)       7           3     Normal                                Levetiracetam              Recovery

  11     Cerebral atrophy                     Tmp, Occ               Frt, Cbl, Bg, Th                           None                  25          7     Normal                                Levetiracetam              Follow-off

  13     Leftoccipital meningeal thickening   Prt,,Tmp,Occ           Frt, Cbl                                   Total (1 month)       2           2     Normal                                Levetirasetam              Exitus

  14     None                                 Occ                    Frt                                        Total (20 thday)      1           1     Normal                                Levetiracetam              Recovery

  15     None                                 Prt, Occ               Frt                                        Subtotal (15 thday)   2           2     Voltage suppression                   None                       Recovery

  16     Cerebral atrophy                     Tmp, Occ               Frt, CC, insular cortex, cytotoxic edema   Subtotal (15thday)    25          10    Voltage suppression,\                 Levetiracetam,Topiramate   Recovery
                                                                                                                                                        Left sharp waves                                                 

  17     Cerebral atrophy                     Prt, Occ               Th, CC, cytotoxic edema                    Total (3 month)       4           2     Voltage suppression,\                 Levetiracetam              Recovery
                                                                                                                                                        Right sharp waves                                                

  18     Cerebral atrophy                     Occ                    None                                       Subtotal (20thday)    15          3     Normal                                Levetiracetam              Recovery

  19     Hypodensities,\                      Prt, Occ               Th, cytotoxic edema                        Subtotal (15 thday)   35          5     Voltage suppression,\                 Sodyum Valproat            Recovery
         brain edema                                                                                                                                    Left sharp waves                                                 

  20     Normal                               Prt,Occ                Frt, Th,CC, cytotoxic edema                Subtotal (1 month)    18          5     None                                  \-                         Recovery

  21     Cerebral atrophy                     Prt, Occ               None                                       None                  3           \-    None                                  Phenytoin                  Exitus

  22\    Hypodensities,\                      Prt, Occ\              Bg,cytotoxic edema, hemorrhage\            Subtotal (1 month)\   120\        5\    Voltage suppression\                  Levetiracetam\             Tetraplegia\
  23     brain edema\                         Tmp,Occ                Frt, Bg, Bs, CC,\                          None                  30          2     Voltage suppression                   Levetiracetam              Exitus
         Cerebral and cerebellar atrophy                             cytotoxic edema                                                                                                                                     
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Occ, occipital; Prt, parietal; Th, thalamus; Tmp, temporal

Abbreviations: Bg, basal ganglia, Bs,brainstem; Cbl, cerebellum; CC, corpus callosum; CT, computed tomography; EEG, electroencephalography; Frt, frontal; Gd+, gadolinium enhancement;

There is no specific recommendation for the need and timing for follow-up MRI, but imaging findings may persist along with triggering factors ([@B16]). Lesions had resolved only partially in our patients (n=9) who had their follow-up MRI within the first month, and completely in the others imaged later. The association of cytotoxic edema was reported with a worse neurological outcome ([@B25]). We had twelve cases with cytotoxic edema, of which eight recovered completely. Two patients had motor deficits due to concomitant intracranial hemorrhage.

![16 -year old girl after liver transplantation (patient 9). Axial MR images **a.** (T2-weighted) and **b.**and**c.** (fluid- attenuated inversion recovery) demonstrate edema in the occipital lobes and cerebellum. Diffusion-weighted images **d.** with b-1000 and **e.** with apparent diffusion coefficient (ADC) demonstrate increased diffusion in the occipital lobes. After 3 months of treatment, axial MR images **f**. and **g**. and ADC **h**. show normal findings](ijcn-12-016-g001){#F1}

![- year old boy after liver transplantation (patient 1). Axial MR image **a**. (fluid attenuation inversion recovery) demonstrates involvement of bilateral globus pallidi and frontal and occipital lobes. Diffusion-weighted images **b.** with b-1000 and **c.** with apparent diffusion coefficient demonstrate decreased diffusion in the occipital lobes and globus pallidus](ijcn-12-016-g002){#F2}

Although this is not the largest series of pediatric PRES, its strengths lie in its single-center character, the inclusion of a considerable sub-series of transplant patients, the young age of patients (including two under 2 yr of age), and in particular, the uniform nature of imaging procedures, i.e., ADC mapping in all patients and evaluate by two neuroradiologists. Its limitations are the retrospective methodology and the different timing of follow-up images.

**In conclusion,** early imaging of at-risk patients for PRES, longitudinal and frequent imaging during and after the episode of PRES would be of importance to establish the hemodynamic changes taking part in the pathogenesis. However, the critical clinical condition of these patients often precludes such studies, and retrospective evaluations continue to contribute to the pool of knowledge in this disorder.
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